MARKET

PRGO

PRGO

Perrigo Co Plc
NYSE
31.27
+0.04
+0.13%
After Hours: 31.27 0 0.00% 16:20 04/25 EDT
OPEN
31.10
PREV CLOSE
31.23
HIGH
32.12
LOW
30.79
VOLUME
1.08M
TURNOVER
0
52 WEEK HIGH
40.28
52 WEEK LOW
25.52
MARKET CAP
4.24B
P/E (TTM)
-333.0138
1D
5D
1M
3M
1Y
5Y
Health Care Sector Update for 04/25/2024: LAB, PRGO, BMY, AZN
NASDAQ · 4h ago
Tourlite Capital Q1 2024 Investor Letter
Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0%, compared to the S&P 500 and Russell 2000.
Seeking Alpha · 10h ago
Perrigo gets offer to sell its HRA Pharma rare diseases unit
Perrigo gets offer to sell its HRA Pharma rare diseases unit to Esteve Healthcare for a total consideration of up to €275 million. The firm expects to use the net proceeds for debt repayment. The proposed deal is expected to close in the third quarter of 2024.
Seeking Alpha · 13h ago
BRIEF-Perrigo Receives Binding Offer To Divest Its HRA Pharma Rare Diseases Business For Up To €275 Mln
Perrigo Receives Binding Offer To Divest Its HRA Pharma Rare Diseases Business For Up To €275 Mln. Perrigo receives offer to sell business for up to €275 million. The company expects to use the money to pay off debt and invest in new products.
Reuters · 14h ago
Perrigo Secures Binding Offer To Divest Its HRA Pharma Rare Diseases Business For Up To €275M
The total consideration of up to €275 million is expected to include an upfront cash payment of €190 million. The Rare Diseases business is to be sold to Perrigo in a deal expected to close in the third quarter of 2024. The deal includes potential earnout payments based on sales milestones.
Benzinga · 14h ago
PERRIGO COMPANY PLC - TOTAL CONSIDERATION WOULD BE ACCRETIVE TO PERRIGO'S CURRENT ENTERPRISE VALUE-TO-EBITDA MULTIPLE
Reuters · 14h ago
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care. Total Purchase Consideration of up to €275 million, consisting of €190 million in Cash Upfront and €85 million in Potential Earnouts. The proposed transaction is expected to close in the third quarter of 2024. Esteve Healthcare, S.L. Has signed a binding offer to acquire Perriga's HRA Pharma Rare Diseases business.
PR Newswire · 14h ago
99% Of This Perrigo Insider's Holdings Were Sold
Perrigo Company plc's (NYSE:PRGO) insiders sold shares in the last year. The biggest insider sale was by Murray Kessler for US$7.1m worth of shares at US$35.75 per share. In the last quarter, Perrigo insiders bought US$526k of shares. The company owns 0.5% of Perriga. But the company has sold more shares than it bought in the past 12 months. It's a good sign to see an insider sale of shares in a company.
Simply Wall St · 1d ago
More
About PRGO
Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.

Webull offers Perrigo Company PLC stock information, including NYSE: PRGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRGO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRGO stock methods without spending real money on the virtual paper trading platform.